Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
News articleYahoo Finance· January 12, 2026
NVIDIA BioNeMo Platform Adopted by Life Sciences Leaders to Accelerate AI-Driven Drug Discovery
View original at finance.yahoo.comNVIDIA BioNeMo Platform Adopted by Life Sciences Leaders to Accelerate AI-Driven Drug Discovery NVIDIA NVIDIA BioNeMoNVIDIA today announced a major expansion of NVIDIA BioNeMo, an open development platform that enables lab-in-the-loop workflows to develop breakthroughs in AI-driven biology and drug discovery…
O que extraímos desta fonte
The claims Via News extracted from this document. We point to the source; we don't replace it.
Artificial intelligence coupled with laboratory automation will transform how scientific work is performed
80% confidenceThe collaboration can help customers work faster, improve accuracy and get more value out of each experiment
80% confidenceLilly is moving toward a future where discovery is driven by rapid experimentation and increasingly customized models
80% confidenceThe co-innovation lab is a catalyst for capabilities that will define the next era of drug discovery
80% confidenceBiology and drug discovery are reaching their transformer moments
80% confidenceBioNeMo turns experimental data into usable intelligence for AI, creating a continuous learning cycle that speeds up discovery
80% confidence
Citado nestas reportagens da Via News
- Denmark's Novo Nordisk Outsources Drug R&D as US Firms Patent the AI Layer Beneath Biology →
- MindWalk's Biology Database Hits 660 Million Patterns as Pharma Outsources Drug R&D →
- NVIDIA BioNeMo Becomes Global Pharma's AI Backbone as Novo Nordisk Outsources Parkinson's R&D →
- NVIDIA BioNeMo Platform Adopted by Eli Lilly and Thermo Fisher for AI Drug Discovery →
- NVIDIA BioNeMo Platform Deployed by Global Pharma Giants for AI Drug Discovery in 2026 →
- NVIDIA BioNeMo Platform Gains Thermo Fisher and Eli Lilly Adoption as Biological AI Market Expands →
- NVIDIA BioNeMo Platform Secures Eli Lilly and Thermo Fisher Partnerships for AI Drug Discovery Infrastructure →
- NVIDIA BioNeMo Platform Secures Partnerships with Eli Lilly, Thermo Fisher for AI Drug Discovery →
- NVIDIA BioNeMo Secures Eli Lilly and Thermo Fisher as Platform Wars Erupt in Global Pharma AI →
- NVIDIA BioNeMo Wins Lilly, Thermo Fisher Deals as Global Biotech AI Platform Race Accelerates →
- NVIDIA Captures Global Drug Discovery AI Market Through Eli Lilly, Thermo Fisher Deals →
- NVIDIA GPU Power Fuels Global Boom in AI Drug Discovery Startups →
- NVIDIA Locks Down Global Pharma AI Infrastructure Through Eli Lilly, Thermo Fisher Platform Deals →
- NVIDIA Locks Eli Lilly and Thermo Fisher Into AI Drug Discovery Platform as Pharma R&D Goes Structural →
- NVIDIA Locks Global Pharma Into AI Drug Discovery as Novo Nordisk Surges 24.9% →
- NVIDIA Locks In Eli Lilly and Thermo Fisher as BioNeMo Becomes Global Pharma AI Backbone →
- NVIDIA Locks Lilly and Thermo Fisher Into BioNeMo as Global Drug Discovery Platform Race Intensifies →
- NVIDIA Secures Eli Lilly and Thermo Fisher for BioNeMo Drug Discovery Platform as Pharma AI Infrastructure Consolidates →
- NVIDIA Secures Thermo Fisher and Eli Lilly as Global Biotech AI Platform Race Intensifies →
- NVIDIA Secures Thermo Fisher, Eli Lilly Partnerships for BioNeMo Drug Discovery Platform →
- NVIDIA's AI Platform Powers Drug Discovery at Thermo Fisher, Eli Lilly in $1.6 Trillion Pharma Market Push →
- NVIDIA's BioNeMo Aims to Become the Global Infrastructure Layer for Drug Discovery →
- NVIDIA's BioNeMo Becomes Global Drug Discovery Infrastructure as Eli Lilly and Thermo Fisher Join Platform →
- NVIDIA's BioNeMo Becomes Global Drug Discovery Infrastructure as Pharma Outsources R&D to AI Platforms →